Peplin maintains clinical trial ambitions

By Renate Krelle
Wednesday, 09 February, 2005

Peplin Biotech's (ASX:PEP) half-year results have revealed a AUD$13 million cash balance -- enough, the company says, to complete three Phase II clinical trials of its skin cancer treatment PEP005.

Just over $9.5 million of the balance came from a share issue to existing shareholders and institutions in December. The figures also show a final AUD$1.8 million termination payment from its collaboration with US company Allergan. Research and development expenses during the period rose $0.9 million, in line with increased product development activities, to $6.2 million. Peplin's net loss before and after tax was $4.1 million compared with a net loss of $3.9 million for the corresponding period last year.

After a discouraging second-half of 2004, during which Allergan handed back the rights to PEP005's development, Peplin was boosted recently by a Phase I safety and tolerability trial for PEP005. In 40 per cent of cases, a single application of its PEP005 topical gel for pre-cancerous skin 'sunspots' completely or substantially cleared the volunteers' actinic keratoses (AK), compared with 15 per cent for placebo patients.

"The positive Phase I trial results fundamentally validate our decision late last year to reacquire the product rights and to take forward the clinical trial program on our own," said CEO Michael Aldridge.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd